The management of acute hypertension in patients with renal dysfunction: labetalol or nicardipine?

Joseph Varon, Karina M. Soto-Ruiz, Brigitte M. Baumann, Pierre Borczuk, Chad M. Cannon, Abhinav Chandra, David Martin Cline, Deborah B. Diercks, Brian Hiestand, Amy Hsu, Preeti Jois-Bilowich, Brian Kaminski, Phillip Levy, Richard M. Nowak, Jon W. Schrock, W. Frank Peacock

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

To compare the safety and efficacy of U.S. Food and Drug Administration (FDA)-recommended doses of labetalol and nicardipine for hypertension (HTN) management in a subset of patients with renal dysfunction (RD). Randomized, open label, multicenter prospective clinical trial. Thirteen United States tertiary care emergency departments. Subgroup analysis of the Evaluation of IV Cardene (Nicardipine) and Labetalol Use in the Emergency Department (CLUE) clinical trial. The subjects were 104 patients with RD (i.e., creatinine clearance < 75 mL/min) who presented to the emergency department with a systolic blood pressure (SBP) ≥ 180 mmHg on 2 consecutive readings and for whom the emergency physician felt intravenous antihypertensive therapy was desirable. The FDA recommended doses of either labetalol or nicardipine for HTN management. The number of patients achieving the physician's predefined target SBP range within 30 minutes of treatment. Patients treated with nicardipine were within target range more often than those receiving labetalol (92% vs. 78%, P = 0.046). On 6 SBP measures, patients treated with nicardipine were more likely to achieve the target range on either 5 or all 6 readings than were patients treated with labetalol (46% vs. 25%, P = 0.024). Labetalol patients were more likely to require rescue medication (27% vs. 17%, P = 0.020). Adverse events thought to be related to either treatment group were not reported in the 30-minute active study period, and patients had slower heart rates at all time points after 5 minutes (P < 0.01). In severe HTN with RD, nicardipine-treated patients are more likely to reach a target blood pressure range within 30 minutes than are patients receiving labetalol. Within 30 minutes of administration, nicardipine is more efficacious than labetalol for acute blood pressure control in patients with RD.

Original languageEnglish (US)
Pages (from-to)124-130
Number of pages7
JournalPostgraduate Medicine
Volume126
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Labetalol
Nicardipine
Hypertension
Kidney
Blood Pressure
Hospital Emergency Service
United States Food and Drug Administration
Reading
Clinical Trials
Physicians
Renal Hypertension
Tertiary Healthcare
Antihypertensive Agents
Creatinine
Emergencies
Therapeutics
Heart Rate

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Varon, J., Soto-Ruiz, K. M., Baumann, B. M., Borczuk, P., Cannon, C. M., Chandra, A., ... Peacock, W. F. (2014). The management of acute hypertension in patients with renal dysfunction: labetalol or nicardipine? Postgraduate Medicine, 126(4), 124-130. https://doi.org/10.3810/pgm.2014.07.2790

The management of acute hypertension in patients with renal dysfunction : labetalol or nicardipine? / Varon, Joseph; Soto-Ruiz, Karina M.; Baumann, Brigitte M.; Borczuk, Pierre; Cannon, Chad M.; Chandra, Abhinav; Cline, David Martin; Diercks, Deborah B.; Hiestand, Brian; Hsu, Amy; Jois-Bilowich, Preeti; Kaminski, Brian; Levy, Phillip; Nowak, Richard M.; Schrock, Jon W.; Peacock, W. Frank.

In: Postgraduate Medicine, Vol. 126, No. 4, 2014, p. 124-130.

Research output: Contribution to journalArticle

Varon, J, Soto-Ruiz, KM, Baumann, BM, Borczuk, P, Cannon, CM, Chandra, A, Cline, DM, Diercks, DB, Hiestand, B, Hsu, A, Jois-Bilowich, P, Kaminski, B, Levy, P, Nowak, RM, Schrock, JW & Peacock, WF 2014, 'The management of acute hypertension in patients with renal dysfunction: labetalol or nicardipine?', Postgraduate Medicine, vol. 126, no. 4, pp. 124-130. https://doi.org/10.3810/pgm.2014.07.2790
Varon, Joseph ; Soto-Ruiz, Karina M. ; Baumann, Brigitte M. ; Borczuk, Pierre ; Cannon, Chad M. ; Chandra, Abhinav ; Cline, David Martin ; Diercks, Deborah B. ; Hiestand, Brian ; Hsu, Amy ; Jois-Bilowich, Preeti ; Kaminski, Brian ; Levy, Phillip ; Nowak, Richard M. ; Schrock, Jon W. ; Peacock, W. Frank. / The management of acute hypertension in patients with renal dysfunction : labetalol or nicardipine?. In: Postgraduate Medicine. 2014 ; Vol. 126, No. 4. pp. 124-130.
@article{64ff8dc3be8a44f0a71d39ec0d241d64,
title = "The management of acute hypertension in patients with renal dysfunction: labetalol or nicardipine?",
abstract = "To compare the safety and efficacy of U.S. Food and Drug Administration (FDA)-recommended doses of labetalol and nicardipine for hypertension (HTN) management in a subset of patients with renal dysfunction (RD). Randomized, open label, multicenter prospective clinical trial. Thirteen United States tertiary care emergency departments. Subgroup analysis of the Evaluation of IV Cardene (Nicardipine) and Labetalol Use in the Emergency Department (CLUE) clinical trial. The subjects were 104 patients with RD (i.e., creatinine clearance < 75 mL/min) who presented to the emergency department with a systolic blood pressure (SBP) ≥ 180 mmHg on 2 consecutive readings and for whom the emergency physician felt intravenous antihypertensive therapy was desirable. The FDA recommended doses of either labetalol or nicardipine for HTN management. The number of patients achieving the physician's predefined target SBP range within 30 minutes of treatment. Patients treated with nicardipine were within target range more often than those receiving labetalol (92{\%} vs. 78{\%}, P = 0.046). On 6 SBP measures, patients treated with nicardipine were more likely to achieve the target range on either 5 or all 6 readings than were patients treated with labetalol (46{\%} vs. 25{\%}, P = 0.024). Labetalol patients were more likely to require rescue medication (27{\%} vs. 17{\%}, P = 0.020). Adverse events thought to be related to either treatment group were not reported in the 30-minute active study period, and patients had slower heart rates at all time points after 5 minutes (P < 0.01). In severe HTN with RD, nicardipine-treated patients are more likely to reach a target blood pressure range within 30 minutes than are patients receiving labetalol. Within 30 minutes of administration, nicardipine is more efficacious than labetalol for acute blood pressure control in patients with RD.",
author = "Joseph Varon and Soto-Ruiz, {Karina M.} and Baumann, {Brigitte M.} and Pierre Borczuk and Cannon, {Chad M.} and Abhinav Chandra and Cline, {David Martin} and Diercks, {Deborah B.} and Brian Hiestand and Amy Hsu and Preeti Jois-Bilowich and Brian Kaminski and Phillip Levy and Nowak, {Richard M.} and Schrock, {Jon W.} and Peacock, {W. Frank}",
year = "2014",
doi = "10.3810/pgm.2014.07.2790",
language = "English (US)",
volume = "126",
pages = "124--130",
journal = "Postgraduate Medicine",
issn = "0032-5481",
publisher = "Medquest Communications LLC",
number = "4",

}

TY - JOUR

T1 - The management of acute hypertension in patients with renal dysfunction

T2 - labetalol or nicardipine?

AU - Varon, Joseph

AU - Soto-Ruiz, Karina M.

AU - Baumann, Brigitte M.

AU - Borczuk, Pierre

AU - Cannon, Chad M.

AU - Chandra, Abhinav

AU - Cline, David Martin

AU - Diercks, Deborah B.

AU - Hiestand, Brian

AU - Hsu, Amy

AU - Jois-Bilowich, Preeti

AU - Kaminski, Brian

AU - Levy, Phillip

AU - Nowak, Richard M.

AU - Schrock, Jon W.

AU - Peacock, W. Frank

PY - 2014

Y1 - 2014

N2 - To compare the safety and efficacy of U.S. Food and Drug Administration (FDA)-recommended doses of labetalol and nicardipine for hypertension (HTN) management in a subset of patients with renal dysfunction (RD). Randomized, open label, multicenter prospective clinical trial. Thirteen United States tertiary care emergency departments. Subgroup analysis of the Evaluation of IV Cardene (Nicardipine) and Labetalol Use in the Emergency Department (CLUE) clinical trial. The subjects were 104 patients with RD (i.e., creatinine clearance < 75 mL/min) who presented to the emergency department with a systolic blood pressure (SBP) ≥ 180 mmHg on 2 consecutive readings and for whom the emergency physician felt intravenous antihypertensive therapy was desirable. The FDA recommended doses of either labetalol or nicardipine for HTN management. The number of patients achieving the physician's predefined target SBP range within 30 minutes of treatment. Patients treated with nicardipine were within target range more often than those receiving labetalol (92% vs. 78%, P = 0.046). On 6 SBP measures, patients treated with nicardipine were more likely to achieve the target range on either 5 or all 6 readings than were patients treated with labetalol (46% vs. 25%, P = 0.024). Labetalol patients were more likely to require rescue medication (27% vs. 17%, P = 0.020). Adverse events thought to be related to either treatment group were not reported in the 30-minute active study period, and patients had slower heart rates at all time points after 5 minutes (P < 0.01). In severe HTN with RD, nicardipine-treated patients are more likely to reach a target blood pressure range within 30 minutes than are patients receiving labetalol. Within 30 minutes of administration, nicardipine is more efficacious than labetalol for acute blood pressure control in patients with RD.

AB - To compare the safety and efficacy of U.S. Food and Drug Administration (FDA)-recommended doses of labetalol and nicardipine for hypertension (HTN) management in a subset of patients with renal dysfunction (RD). Randomized, open label, multicenter prospective clinical trial. Thirteen United States tertiary care emergency departments. Subgroup analysis of the Evaluation of IV Cardene (Nicardipine) and Labetalol Use in the Emergency Department (CLUE) clinical trial. The subjects were 104 patients with RD (i.e., creatinine clearance < 75 mL/min) who presented to the emergency department with a systolic blood pressure (SBP) ≥ 180 mmHg on 2 consecutive readings and for whom the emergency physician felt intravenous antihypertensive therapy was desirable. The FDA recommended doses of either labetalol or nicardipine for HTN management. The number of patients achieving the physician's predefined target SBP range within 30 minutes of treatment. Patients treated with nicardipine were within target range more often than those receiving labetalol (92% vs. 78%, P = 0.046). On 6 SBP measures, patients treated with nicardipine were more likely to achieve the target range on either 5 or all 6 readings than were patients treated with labetalol (46% vs. 25%, P = 0.024). Labetalol patients were more likely to require rescue medication (27% vs. 17%, P = 0.020). Adverse events thought to be related to either treatment group were not reported in the 30-minute active study period, and patients had slower heart rates at all time points after 5 minutes (P < 0.01). In severe HTN with RD, nicardipine-treated patients are more likely to reach a target blood pressure range within 30 minutes than are patients receiving labetalol. Within 30 minutes of administration, nicardipine is more efficacious than labetalol for acute blood pressure control in patients with RD.

UR - http://www.scopus.com/inward/record.url?scp=84907957229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907957229&partnerID=8YFLogxK

U2 - 10.3810/pgm.2014.07.2790

DO - 10.3810/pgm.2014.07.2790

M3 - Article

C2 - 25141250

AN - SCOPUS:84907957229

VL - 126

SP - 124

EP - 130

JO - Postgraduate Medicine

JF - Postgraduate Medicine

SN - 0032-5481

IS - 4

ER -